A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer
A combination of S-1 and cisplatin is recognized as one of the standard first-line chemotherapy regimens for patients with advanced gastric cancer. However, demographic analyses of pivotal phase III studies have showed that only a minority of treated patients were aged 76 years or older. The purpose of this phase II study was to evaluate the safety and efficacy of combination therapy with S-1 and cisplatin in elderly patients with chemotherapy-naive advanced gastric cancer.
Patients aged 76 years or older received S-1 40 mg/m2 orally twice daily for 21 days and cisplatin 60 mg/m2 intravenously infused at day 8 of each 35-day cycle. Dose modification was performed according to creatinine clearance. The primary endpoint was overall survival (OS). Secondary endpoints included response rate, progression-free survival (PFS), time to treatment failure (TTF), and adverse events.
A total of 40 patients were enrolled. Median OS was 12.3 months, PFS was 7.8 months, and TTF was 4.3 months. The response rate was 54%. The most common grade 3–4 adverse events were anorexia (25%), neutropenia (23%), hyponatremia (20%), anemia (18%), and febrile neutropenia (8%). No treatment-related death occurred.
Combination chemotherapy with S-1 and cisplatin is an effective and well-tolerated regimen for elderly patients with advanced gastric cancer when the dose is adjusted according to renal function.
KeywordsCisplatin Elderly patient Gastric cancer S-1
- 1.GLOBOCAN database: http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp. Accessed 02 May 2017.
- 2.Center for Cancer Control and Information Services, National Cancer Center, Japan: http://ganjoho.jp/public/cancer/stomach/. Accessed 02 May 2017.
- 7.Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547–53.CrossRefPubMedGoogle Scholar
- 10.Koizumi W, Akiya T, Sato A, Sakuyama T, Sasaki E, Tomidokoro T, et al. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo cooperative oncology group study. Cancer Chemother Pharmacol. 2010;65:1093–9.CrossRefPubMedGoogle Scholar
- 11.Vanita N. Guidelines for chemotherapy and dosing modifications. In: Chu E, DeVita Jr VT, editors. Physicians’ cancer chemotherapy drug manual. Sudbury: Jones and Bartlett; 2007. p. 388–9.Google Scholar
- 13.The Japanese Society of Nephrology and Pharmacotherapy, Japan. Available from: https://www.jsnp.org/docs/JSNP-yakuzai_dosing_30.pdf. Accessed 02 May 2017.
- 15.Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–42.CrossRefPubMedGoogle Scholar
- 18.Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, et al. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer. 2006;6:125.CrossRefPubMedPubMedCentralGoogle Scholar